In 2011, a report by JD Lewis et al. titled “Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.” published in Diabetes Care states “studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy” and as such, this was…

In August 2013, an article titled “Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.” was published by F.Y. Hsiao et al. in the medical journal Drug Safety that aimed to evaluate the connection between rosiglitazone (Avandia) and bladder cancer and between pioglitazone (Actos) and bladder…

In 2013, a team of researchers led by RM Turner published a report in British Journal of Clinical Pharmacology that evaluated the connection between the thiazolidinedione class of drugs and the onset of bladder cancer.  Drugs in that class include diabetes drugs Avandia and Actos.

Evaluating 18 previously-conducted studies (13 observational studies and 5 randomized…

In 2013, a report by M. Ferwana et al. titled “Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.” was published in Diabetes Medicine that sought to evaluate the connection between the diabetes drug Actos and new-onset bladder cancer.

Living up to its name, this report reviewed data from six previous…

In 2012, a study by Z. Zhu et al. titled “Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.” aimed to “examine the association between pioglitazone therapy and bladder cancer in patients with diabetes.”  To be clear, “pioglitazone” is the chemical name for the diabetes drug Actos…

An article published in a 2013 edition of Tumour Biology titled “Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.” by S. He et al. aimed to determine the risk for bladder cancer associated with use of pioglitazone (Actos; Tadeka Pharmaceuticals, Inc.).

The authors…

In 2012, A. Neumann et al. published a study titled “Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.” in Diabetologica that studied the risk for bladder cancer among French diabetic patients using Actos (pioglitazone), a drug used to control blood sugar manufactured by Tadeka Pharmaceuticals, Inc.…

If anyone in Washington is looking for help with a potential Actos bladder cancer case, give me a call.  I have an office in Redmond and am accepting cases from people all across the state, including as far away as Spokane and as close as Bellevue.  I am happy to help anyone who is…